Accumulation patterns must have someone big behind them... guess it is a good time to remind any newcomers of some past , key comments made by Mr Worsley of Peregrine Pharmaceuticals.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!